In a mouse model of liver cancer, lenvatinib (a dual inhibitor of VEGFR and FGFR) reduced the expression of PD-1 on T cells, and PD-L1 on tumor and umbilical vascular endothelial cells. This evidence concerns the gene KDR and neoplasm.